Psoriasis News

Clinically and Statistically Significant Reduction of Chronic Pruritus Seen in Psoriasis Patients Creabilis, a late stage European dermatology company with a focus on chronic pruritus , has announced headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients.

Stocks in the News is produced by Ransom Notes Radio and Goodfellow, LLC . Crista Huff manages Goodfellow LLC, a website that recommends outperforming stocks using fundamental and technical analysis.

Creabilis, a late stage European dermatology company with a focus on chronic pruritus , today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients.

Idera Pharmaceuticals released positive data on its Phase 2 trial of IMO-3100, a candidate for the treatment of psoriasis, an autoimmune disease that results in inflammation of the skin and join problems and is linked with other conditions such as diabetes, heart disease and depression.

Rashes and lesions on the skin are common symptoms of psoriasis, an autoimmune disease that often gets mistaken for eczema.

Psoriasis is reportedly the most prevalent autoimmune illness in the U.S. and the National Psoriasis Foundation is leading the charge to find a cure for the skin disease.

Biotechnology major Biocon plans to launch in July its novel biologic drug Itolizumab branded as 'Alzumab' to be used for the treatment of chronic plaque psoriasis in the country.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! The active ingredient in a drug that's expected to become a popular treatment for multiple sclerosis has been linked to four European cases of a rare but sometimes fatal brain disease called progressive multifocal leukoencephalopathy .

A synthetic form of Vitamin D might ease the impact of chronic liver disease, the Salk Institute for Biological Studies announced Thursday.

Biogen Idec Inc.'s Fumaderm, an early formulation of the company's just approved multiple sclerosis pill Tecfidera, was tied to three cases of a brain infection more often linked to its potent medication Tysabri.